Dr. Tsimberidou on the Next Steps for Personalized Care

Apostolia Tsimberidou, MD, PhD
Published: Wednesday, Jul 27, 2011

Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, explains the next steps for personalized cancer care. She believes it involves continuing to test patients for molecular aberrations and selecting the correct patients for early drug development.

Tsimberidou states there is still a need to understand the emergence of resistance to targeted therapies and the complexities of targeting more than one aberration or using the combination of multiple targeted therapies. She mentions MD Anderson Cancer Center's goal is for personalized treatments to be fully reimbursed and for it to become the standard of care in the future.
Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, explains the next steps for personalized cancer care. She believes it involves continuing to test patients for molecular aberrations and selecting the correct patients for early drug development.

Tsimberidou states there is still a need to understand the emergence of resistance to targeted therapies and the complexities of targeting more than one aberration or using the combination of multiple targeted therapies. She mentions MD Anderson Cancer Center's goal is for personalized treatments to be fully reimbursed and for it to become the standard of care in the future.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x